The Reliability of FEbrile Neutropenia After ChEmotherapy (FENCE) Scores in Predicting Granulocyte Colony-stimulating Factor Breakthrough Febrile Neutropenia Among Patients with Lymphoma Undergoing First-cycle Chemotherapy: A Prospective...

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2023 Mar 30

PMID 36993799

Authors

Pravinwan Thungthong

Supat Chamnanchanunt

Tawatchai Suwanban

Chajchawan Nakhahes

Kunapa Iam-Arunthai

Tananchai Akrawikrai

Udomsak Bunworasate

Ponlapat Rojnuckarin

Affiliations

Soon will be listed here.

Abstract

Background: A tool for estimating risk of febrile neutropenia (FN) after chemotherapy, namely the FEbrile Neutropenia after ChEmotherapy (FENCE) score, has been developed but has not been widely validated. This study aimed to validate the FENCE score as a tool for predicting granulocyte colony-stimulating factor (G-CSF) breakthrough FN among patients with lymphoma who underwent chemotherapy.

Methods: This was a prospective observational study of treatment-naive adult patients with lymphoma who underwent their first cycle of chemotherapy between 2020 and 2021. The patients were followed up until the next cycle of chemotherapy to identify any infection events.

Results: Among the 135 patients with lymphoma, 62 (50%) were men. In a comparison of the value of each FENCE parameter for predicting G-CSF breakthrough infection, the parameter of advanced-stage disease showed high sensitivity of 92.8%, and receipt of platinum chemotherapy showed high specificity of 95.33%. With a FENCE score of 12 as a cutoff for low risk, analysis across all patients with lymphoma resulted in a high AUROCC of 0.63 (95% CI = 0.5-0.74%; = 0.059), and analysis across only patients with diffuse large B-cell lymphoma (DLBCL) resulted in an AUROCC of 0.65 (95% CI = 0.51-0.79%; = 0.046). With a cutoff point of 12, FENCE score can predict breakthrough infection events at 30.0% (95% CI = 17.8-47.4%).

Conclusion: This study divided patients with lymphoma into risk groups according to FENCE score, showing that this instrument has discriminatory ability in predicting FN events, these being more likely to occur in patients in the intermediate- and high-risk groups. Multicenter studies are needed to validate this clinical risk score.

References

Hansen B, Wendelbo O, Bruserud O, Hemsing A, Mosevoll K, Reikvam H . Febrile Neutropenia in Acute Leukemia. Epidemiology, Etiology, Pathophysiology and Treatment. Mediterr J Hematol Infect Dis. 2020; 12(1):e2020009. PMC: 6951355. DOI: 10.4084/MJHID.2020.009. View

Johnson P, Yi A, Horick N, Amonoo H, Newcomb R, Lavoie M . Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive Non-Hodgkin Lymphoma. Oncologist. 2021; 26(11):965-973. PMC: 8571763. DOI: 10.1002/onco.13915. View

Crawford J, Dale D, Lyman G . Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004; 100(2):228-37. DOI: 10.1002/cncr.11882. View

Zheng B, Toarta C, Cheng W, Taljaard M, Reaume N, Perry J . Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and.... Crit Rev Oncol Hematol. 2020; 149:102922. DOI: 10.1016/j.critrevonc.2020.102922. View

Zatarah R, Faqeer N, Quraan T, Mahmoud A, Matalka L, Abu Khadija L . Validation of the FENCE Risk Groups for Prediction of Febrile Neutropenia With First-Cycle Chemotherapy. JNCI Cancer Spectr. 2022; 6(3). PMC: 9188319. DOI: 10.1093/jncics/pkac038. View

Wolff T, Schulz H, Losem C, Reichert D, Hurtz H, Sandner R . Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study). Eur J Haematol. 2018; 102(2):174-181. DOI: 10.1111/ejh.13189. View

Lyman G, Abella E, Pettengell R . Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol. 2014; 90(3):190-9. DOI: 10.1016/j.critrevonc.2013.12.006. View

Link H . Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF). Support Care Cancer. 2022; 30(9):7067-7077. PMC: 9225876. DOI: 10.1007/s00520-022-07103-5. View

Lyman G, Kuderer N . The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol. 2004; 50(2):129-46. DOI: 10.1016/j.critrevonc.2004.01.001. View

10.

Cornes P, Gascon P, Chan S, Hameed K, Mitchell C, Field P . Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia. Adv Ther. 2018; 35(11):1816-1829. PMC: 6223993. DOI: 10.1007/s12325-018-0798-6. View

11.

Aagaard T, Roen A, Reekie J, Daugaard G, de Nully Brown P, Specht L . Development and Validation of a Risk Score for Febrile Neutropenia After Chemotherapy in Patients With Cancer: The FENCE Score. JNCI Cancer Spectr. 2019; 2(4):pky053. PMC: 6649794. DOI: 10.1093/jncics/pky053. View

12.

Cainap C, Cetean-Gheorghe S, Pop L, Leucuta D, Piciu D, Mester A . Continuous Intravenous Administration of Granulocyte-Colony-Stimulating Factors-A Breakthrough in the Treatment of Cancer Patients with Febrile Neutropenia. Medicina (Kaunas). 2021; 57(7). PMC: 8305666. DOI: 10.3390/medicina57070675. View

13.

Averin A, Silvia A, Lamerato L, Richert-Boe K, Kaur M, Sundaresan D . Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice. Support Care Cancer. 2020; 29(4):2179-2186. PMC: 7892737. DOI: 10.1007/s00520-020-05715-3. View

14.

McBride A, Krendyukov A, Mathieson N, Campbell K, Balu S, Natek M . Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma. J Med Econ. 2019; 23(1):28-36. DOI: 10.1080/13696998.2019.1658591. View

15.

Edelsberg J, Weycker D, Bensink M, Bowers C, Lyman G . Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years. Curr Med Res Opin. 2019; 36(3):483-495. DOI: 10.1080/03007995.2019.1703665. View

16.

Lyman G . Risk assessment in oncology clinical practice. From risk factors to risk models. Oncology (Williston Park). 2003; 17(11 Suppl 11):8-13. View